Annexon

Annexon FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Annexon (ANNX) as of Oct 11, 2026 is 90.23 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 85.40 % — a change of 5.66% (higher).

FCF Conversion

90.23 %

YoY

5.66%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Annexon is 2025 90.23 % . FCF Conversion Rate (FCF/EBITDA) of Annexon was 2024 85.40 % . It decreases by 5.66% higher compared to the previous year.

The Annexon FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
94.01 USD
Jan 1, 2019
76.98 USD
Jan 1, 2020
85.35 USD
Jan 1, 2021
84.33 USD
Jan 1, 2022
88.82 USD
Jan 1, 2023
90.39 USD
Jan 1, 2024
85.40 USD
Jan 1, 2025
90.23 USD
The Annexon FCF Conversion history
YEARFCF ConversionYoY
90.23 %+5.66%
85.40 %-5.52%
90.39 %+1.76%
88.82 %+5.33%
84.33 %-1.19%
85.35 %+10.86%
76.98 %-18.11%
94.01 %-11.30%
105.98 %—
Access this data via the Eulerpool API

Annexon Stock analysis

What does Annexon do? Annexon Inc is a biopharmaceutical company based in South San Francisco, California. It was founded in 2011 by Doug Love, Ted Love, and Arnon Rosenthal, who had previously worked at major pharmaceutical companies such as Genentech and Novartis. The company's main goal is to develop new treatment options for neurodegenerative diseases, focusing on the development of drugs that target the autophagy process in cells to reduce damage to nerve cells and alleviate symptoms. Annexon Inc has two divisions, Annexon Biosciences and Annexon Clinical, with partnerships with renowned pharmaceutical companies to advance drug development. Its main product is ANX005, a therapeutic antibody protein that targets the role of the complement system in neurodegenerative diseases. Annexon Inc has received multiple awards for its work and innovations and has a dedicated team of scientists and executives committed to improving the lives of people with neurodegenerative diseases. Annexon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Annexon stock

FCF Conversion Rate (FCF/EBITDA) of Annexon is 90.23 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Annexon changed from 85.40 % to 90.23 %, representing a 5.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Annexon since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Annexon with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Annexon

All Key Metrics — Annexon